Liver disease
Drug research and approvals for liver disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,702 studies of liver disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 1 approved and 7 open orphan designations naming it, and the EU has 8 authorised medicines for it.
- Recruiting worldwide: 1,702
- Trials authorized in Canada: 26
- FDA orphan approvals: 1
- EU medicines: 8
- Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab…NCT07951021 · Phase 2 · Sun Yat-sen University · starts Oct 15, 2026
- Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to…NCT07947342 · Phase 2 · Sun Yat-sen University · starts Oct 20, 2026
- A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal…NCT07944482 · Phase 1 · Fujian Akeylink Biotechnology Co., Ltd. · starts Jul 3, 2026
- Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 DiabetesNCT07928661 · Phase 2 · Universitas Sriwijaya · starts Jul 29, 2026
- Artificial Intelligence-Assisted Imaging for Diagnosis and Management of Focal Liver LesionsNCT07926672 · Not applicable · Sun Yat-sen University · starts Dec 15, 2026
- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma…NCT07924943 · Not applicable · AIO-Studien-gGmbH · starts Jul 28, 2026
- The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated CirrhosisNCT07920744 · Not reported · Fifth Affiliated Hospital, Sun Yat-Sen University · starts Oct 28, 2026
- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisNCT07923318 · Not applicable · Chonnam National University Hospital · starts Oct 4, 2026
Approved 7
- AvatrombopagThrombopoietin receptor agonist
- EntecavirDNA polymerase/reverse transcriptase inhibitor
- MetreleptinLeptin receptor agonist
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Gadoxetic acid
- Cholic acid
- Cysteine
Phase 3 12
- UrsodiolBile acid receptor FXR agonist
- BupivacaineSodium channel protein type IV alpha subunit blocker
- FentanylMu opioid receptor agonist
- HydromorphoneMu opioid receptor agonist
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- Fibrinogen, humanFibrinogen exogenous protein
- Dextrose
- Gabexate
- Ademetionine
- Vitamin e
- Biphenyl dimethyl dicarboxylate
Phase 2 12 of 21
- Cagrilintide
- AlemtuzumabCAMPATH-1 antigen inhibitor
- CyclosporineCyclophilin A modulator
- EltrombopagThrombopoietin receptor agonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- SemaglutideGlucagon-like peptide 1 receptor agonist
- SirolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- PentoxifyllineAdenosine A2 receptor antagonist
- AmlodipineVoltage-gated L-type calcium channel blocker
- MivacuriumMuscle-type nicotinic acetylcholine receptor antagonist
- ColesevelamBile acids sequestering agent
Phase 1 or earlier 12 of 219
- EnasidenibIsocitrate dehydrogenase [NADP], mitochondrial inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- FedratinibTyrosine-protein kinase receptor FLT3 inhibitor
- ApalutamideAndrogen Receptor antagonist
- Bardoxolone methylPeroxisome proliferator-activated receptor gamma antagonist
- Edaravone
- DaridorexantOrexin receptor antagonist
- BedaquilineATP synthase inhibitor
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- CisplatinDNA inhibitor
- DeferasiroxIron chelating agent
- DelafloxacinBacterial DNA gyrase inhibitor
How its trials ended
2,245 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 381 whose ending is known, 45% met their primary endpoint, 8% missed it and 47% stopped early.
- Completed, result not reported92141%
- Ongoing57526%
- Status unknown36816%
- Met its primary endpoint1708%
- Stopped: other or unclear974%
- Stopped: enrollment or feasibility442%
- Missed its primary endpoint311%
- Stopped: sponsor or business decision151%
- Stopped: lack of efficacy11<1%
- Stopped: funding11<1%
- Stopped: safety2<1%
| Jul 14, 2026 | A dose-finding, double-blind, randomized, placebo-controlled phase 2 study to evaluate the efficacy and safety of treatment with efimosfermin alfa in adult…Efimosfermin alfa (GSK6519754) | GSK | Ongoing |
| May 7, 2026 | A phase 1/2, open-label, multi-center, dose escalation, dose expansion, and single repeat dose study of TSRA-196 in adults with the pizz genotype who have lung…TSRA-196 | Tessera Therapeutics, Inc. | Pending |
| Nov 6, 2025 | A master protocol for a randomized, controlled, clinical trial of multiple pharmacologic agents in adult participants with metabolic dysfunction-associated…Retatrutide (LY3437943) / Tirzepatide (LY3298176) | Eli Lilly | Ongoing |
| Mar 28, 2025 | Stimulating adipose tissue fatty acid disposal with low-dose, postprandial, intermittent niacin for the treatment of metabolic dysfunction-associated steatotic…Nicotinic acid / Albumin / 11C palmitate / 18F ftha | Ciusss De L'Estrie - Centre Hospitalier Universitaire De Sherbrooke | Pending |
| Mar 7, 2025 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of denifanstat in patients with metabolic dysfunction…Denifanstat (TVB-2640) | Sagimet Biosciences | Closed |
| Oct 29, 2024 | A dose-finding, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of GSK4532990 for steatohepatitis in adults with alcohol…GSK4532990 | GSK | Ongoing |
| May 31, 2024 | A phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of NST-6179 in adult…Orziloben (NST-6179) | Northsea Therapeutics B.V. | Closed |
| Feb 14, 2024 | Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver…NNC0194-0499 / Cagrilintide-semaglutide/ Cagrilintide/ Semaglutide | Novo Nordisk | Ongoing |
| Jan 23, 2024 | A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of fazirsiran in the treatment of ALPHA-1 antitrypsin…Fazirsiran (TAK-999) | Takeda Pharmaceuticals USA | Ongoing |
| Sep 12, 2023 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed…Efruxifermin (EFX) | Akero Therapeutics | Ongoing |
| Jul 27, 2018 | OmegavenOmegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC) | Fresenius Kabi USA, LLC | Approved |
| Feb 12, 2026 | Fully synthetic medium-chain fatty acid analogueTreatment of intestinal failure associated liver disease | NorthSea Therapeutics B.V. | Designated |
| Sep 15, 2021 | OctreotideTreatment of autosomal dominant polycystic liver disease | Camurus AB | Designated |
| Mar 28, 2018 | FluasteroneTreatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis) | Sterotherapeutics, LLC | Designated |
| May 14, 2014 | Menadione sodium bisulfiteTreatment of autosomal dominant polycystic liver disease | IC-MedTech Corporation | Designated |
| Nov 20, 2013 | EmricasanTreatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease | Conatus Pharmaceuticals Inc. | Designated |
| Apr 15, 2013 | Sodium ascorbate and menadione sodium bisulfiteTreatment of autosomal dominant polycystic liver disease | IC-Medtech Corporation | Designated |
| Oct 23, 2007 | UrsodiolTreatment of cystic fibrosis liver disease | Asklepion Pharmaceuticals, LLC | Designated |
| Mar 26, 2026 | KayshildSemaglutide | Novo Nordisk A/S | EMA ↗ |
| Aug 18, 2025 | RezdiffraResmetirom | Madrigal Pharmaceuticals EU Limited | EMA ↗ |
| Jun 20, 2019 | DopteletAvatrombopag | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| Sep 25, 2017 | Entecavir AccordEntecavir · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 18, 2017 | Entecavir Viatris (previously Entecavir Mylan)Entecavir · generic | Viatris Limited | EMA ↗ |
| Oct 23, 2009 | Lamivudine TevaLamivudine · generic | Teva B.V. | EMA ↗ |
| Jun 26, 2006 | BaracludeEntecavir | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Jul 29, 1999 | ZeffixLamivudine | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA